Montreal / April 25, 2025 – Clinical researchers at the University of Montreal Hospital Center (CHUM) have published in the journal BMC Cancer the...
March 08, 2025, The CHUM site is activated to begin patient recruitment for safety clinical trials with NexPlasmaGen medical technology Montreal / March 08, 2025...
Montreal / September 19, 2024 - NexPlasmaGen wins the Corporate Livewire magazine's Innovation and Excellence Award - Cancer Treatment Technology Company of 2024 The...
Montreal / August 8, 2024 - NexPlasmaGen is pleased to announce that Mr. David Uffer and Mr. Edward J. Dougherty have joined NexPlasmaGen! David...
Montreal / April 19, 2024 - NexPlasmaGen is honored to announce that it has won GHP magazine's Best MedTech Oncology Business - Canada...
Montreal / April 05, 2024 - NexPlasmaGen is pleased to announce that on February 6, 2024, the 2nd U.S. patent (US 11895763B2) was...
Montreal / October 06, 2023 - NexPlasmaGen received a financial support of $219,500 from Quebec's Ministère de l'économie, de l'innovation et de l'énergie...
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT Canada’s Premier Health Science Investment Event! Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that...